Drug intelligence / Profile preview

ABBV-1758

Development stage: Phase 2
Lead developer: AbbVie
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous, Subcutaneous

Overview

ABBV-1758 is an investigational monoclonal antibody being developed by AbbVie for the treatment of Alzheimer's disease. It is designed to target and clear amyloid-beta (Aβ) protein, a key pathological hallmark of the disease. The drug is currently being evaluated in Phase 1/2 clinical trials to assess its safety, efficacy, and pharmacokinetics when administered via intravenous or subcutaneous routes. Like other anti-amyloid therapies, its goal is to reduce the amyloid burden in the brain to potentially slow cognitive and functional decline in patients with early-stage Alzheimer's disease.

Targets

TFRC (Transferrin Receptor)pE-Aβ (Pyroglutamylated amyloid-β)

Beyond the preview

Go deeper on ABBV-1758.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ABBV-1758.

Explore the full profile